INVENTIVA SA - ADR (IVA)

US46124U1079 - ADR

2.35  -0.02 (-0.84%)

Fundamental Rating

2

IVA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. IVA may be in some trouble as it scores bad on both profitability and health. IVA shows excellent growth, but is valued quite expensive already.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

IVA had negative earnings in the past year.
In the past year IVA has reported a negative cash flow from operations.
In the past 5 years IVA always reported negative net income.
In the past 5 years IVA always reported negative operating cash flow.

1.2 Ratios

IVA has a worse Return On Assets (-264.26%) than 93.27% of its industry peers.
Industry RankSector Rank
ROA -264.26%
ROE N/A
ROIC N/A
ROA(3y)-82.07%
ROA(5y)-64.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

IVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

IVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IVA has been increased compared to 1 year ago.
Compared to 5 years ago, IVA has more shares outstanding
The debt/assets ratio for IVA is higher compared to a year ago.

2.2 Solvency

IVA has an Altman-Z score of -17.97. This is a bad value and indicates that IVA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IVA (-17.97) is worse than 85.49% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.97
ROIC/WACCN/A
WACC7.18%

2.3 Liquidity

A Current Ratio of 0.59 indicates that IVA may have some problems paying its short term obligations.
IVA has a Current ratio of 0.59. This is amonst the worse of the industry: IVA underperforms 92.21% of its industry peers.
IVA has a Quick Ratio of 0.59. This is a bad value and indicates that IVA is not financially healthy enough and could expect problems in meeting its short term obligations.
IVA has a worse Quick ratio (0.59) than 91.86% of its industry peers.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.59

More info and screens

7

3. Growth

3.1 Past

IVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.74%, which is quite impressive.
The Revenue has grown by 10.92% in the past year. This is quite good.
IVA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.46% yearly.
EPS 1Y (TTM)20.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28%
Revenue 1Y (TTM)10.92%
Revenue growth 3Y260.83%
Revenue growth 5Y40.46%
Sales Q2Q%-97.84%

3.2 Future

IVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.08% yearly.
Based on estimates for the next years, IVA will show a very strong growth in Revenue. The Revenue will grow by 57.69% on average per year.
EPS Next Y-9.29%
EPS Next 2Y7.86%
EPS Next 3Y6.21%
EPS Next 5Y10.08%
Revenue Next Year-58%
Revenue Next 2Y39.27%
Revenue Next 3Y43.67%
Revenue Next 5Y57.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.86%
EPS Next 3Y6.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVENTIVA SA - ADR

NASDAQ:IVA (12/20/2024, 8:19:17 PM)

2.35

-0.02 (-0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2024-11-21/amc
Earnings (Next)02-13 2025-02-13/amc
Inst Owners52.71%
Inst Owner Change0.12%
Ins Owners18.09%
Ins Owner ChangeN/A
Market Cap123.05M
Analysts88
Price Target12.72 (441.28%)
Short Float %0.52%
Short Ratio1.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.1%
PT rev (3m)-15.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.83%
EPS NY rev (1m)0%
EPS NY rev (3m)9.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)113.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.14
EYN/A
EPS(NY)-1.56
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0.31
BVpS-1.57
TBVpS-1.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -264.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.07%
ROA(5y)-64.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.93%
Cap/Sales 3.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.59
Altman-Z -17.97
F-Score3
WACC7.18%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.81%
Cap/Sales(5y)20.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28%
EPS Next Y-9.29%
EPS Next 2Y7.86%
EPS Next 3Y6.21%
EPS Next 5Y10.08%
Revenue 1Y (TTM)10.92%
Revenue growth 3Y260.83%
Revenue growth 5Y40.46%
Sales Q2Q%-97.84%
Revenue Next Year-58%
Revenue Next 2Y39.27%
Revenue Next 3Y43.67%
Revenue Next 5Y57.69%
EBIT growth 1Y10.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.44%
EBIT Next 3Y7.99%
EBIT Next 5Y16.13%
FCF growth 1Y-55.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.73%
OCF growth 3YN/A
OCF growth 5YN/A